Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas
Conditions: Neuroendocrine Tumors; Neuroendocrine Carcinoma; Neuroendocrine Cancer Intervention: Drug: Pembrolizumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme Corp. Not yet recruiting - verified September 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials